The antibiotic thiazole compound siomycin, which we have found from the culture broth of Actinomycetes (strain No.806097) in search of antibody production inhibitor, showed the in vitro immunosuppressive property against B-cells stimulated with T-cell independent antigen DNP-LPS (dinitrophenyl-lipopolysaccharide) while it also showed inhibitory effect against Tcell proliferation. Its inhibitory mechanism was considered to be different from that of FK506, the representative of T-cell immunosuppressant. Moreover, siomycin showed inhibitory effect in both T-cell dependent and independent murine antibody production models and decreased the severity in murine collagen arthritis model. Therefore, siomycin is a unique immunosuppressant which has potential for the treatment of some antibody-mediated diseases.
The very high success rate of allotransplantation by using T-cell immunosuppressants such as cyclosporine A and FK506 has led to the establishment of this procedure as a standard therapy for the treatment of acute allograft rejection1,2). However, some problems remain to be solved because such a drug does not exert a satisfactory effect toward other immune syndrome3).
Some immune diseases including rheumatoid arthritis, xenograft rejection or chronic allograft rejection involve the presence of antibody4-6). In xenotranplantation which is the transplantation of organs derived from different species, the loss of xenograft is induced by several causes. One of them is that excessive antibody production, resulting in acute vascular rejection to which current T-cell immunosuppressants show ineffectiveness, is triggered by the transplanted xenograft7). Chronic allograft rejection is a leading to organ loss owing to the obstruction of arterial vessels of the transplanted allograft. Among the numerous contributing factors, antibody plays a critical role in this disease8,9).
Therefore, the sufficient control of antibody production may play a pivotal role in treating the above-mentioned immune diseases. A B-cell immunosuppressant, which is different from typical T-cell immunosuppressants in mode of action, would be expected to have substantial therapeutic potential in andibody-mediated diseases.
We have searched for a potent inhibitor of T-cell independent antibody production by murine B-cells, from the culture broth of Actinomvcetes. Siomycin produced by Actinomvcetes strain No. 806097, known as thiazole antibiotic10), was found to inhibit antibody production by murine B-cells stimulated by T-cell independent antigen, DNP-LPS (dinitrophenyl-lipopolysaccharide).
In this paper, we describe the in vitro and in vivo immunological properties of siomycin, and show the possibility of this compound to be a potent therapeutic drug against andibody-mediated diseases.
Materials and Methods

Media Used for Seed Culture and Production
The seed medium consisted of glucose 0.5%, sucrose 0.5%, yeast extract 0.2%, peptone 0.5%, oatmeal 0.5%, tween80 0.1%, peanuts powder 0.5%, fumic acid 0.01% and CaCO3 0.2%. The production medium (pH=6.5) consisted of glucose 0.5%, MS3600 2.5%, soybean flour 1%, dried yeast 0.5%, L-asparagine 0.2%, K2HPO4 0.05%, NaCl 0.05% and CaCO3 0.2%.
HPLC Analysis
Siomycin was detected by the reverse phase HPLC In Vitro Immunosuppressive Activity
The two assays, in both of which the decline of metabolic activity was an index of the Immunosuppressive property, were performed. One of them was mixed lymphocyte reaction (MLR) assay. In this assay spleen cells from female C57/B6 mice (Charles River Japan Inc.) were irradiated and mixed with the same number of spleen cells from female BALB/c mice (Charles River Japan Inc.) in 96-well U-bottomed plate. Both cells were suspended in the same medium as that used in antibody production assay. intensity is more than five, per total cells were calculated in order to determine the quantity of IgG 1. 0.3, 3 or 30mg/kg/day of siomycin was intraperitoneally administrated (day 0-5).
Murine Collagen Arthritis Models
Male DBA/1 mice, 7 weeks old, (Charles River Japan Inc.) were sensitized with bovine type II collagen and adjuvant complete freund (Wako Jyunnyaku, Japan), and 3 weeks later secondary immunization was performed (10 mice/group). Simultaneously administration of siomycin (0.3, 3 or 30mg/kg/day i.p.) was started (day 0) and proceeded until day 10. Mice were bled on day 11. Total antibody (IgG, IgM and IgA) levels in each serum were determined by ELISA. The degree of arthritis was defined as score of edema of each 4 feet (The conditions were classified into 4 grades; score 0: normal condition, score 1: partial inflammation, score 2: overall inflammation and score 3: inability of bending of articulation). We have observed its severity on day 11. Total scores regarding each 4 feet were expressed as a dot in Fig. 4B . (Fig. 1A) was found to suppress antibody production while this substance also possessed inhibitory action against T-cell proliferation stimulated with alloantigen or soluble anti-CD3 mAb (Table 1) . Moreover, we have investigated whether the related thiazole substance thiostrepton (Fig.   1B ) affect on B-cells and T cells, and we have discovered it exerted the similar effect as siomycin (Table 1) .
On the other hand, T-cell immunosuppressant FK506, which strongly suppresses the activation of T-cells followed by inhibition of B-cell activation and differentiation,
showed only a weak suppressive activity against T-cell independent antibody production ( Table 1) . These results indicate that siomycin and thiostrepton directly work on Bcells whereas FK506 indirectly work on B-cells via T-cell The effects of siomycin on in vivo T-cell independent antibody production were assessed after immunization of female BALB/c mice with DNP-LPS. Administration of 30mg/kg/day (i.p., day 0-3) of siomycin showed suppressive (about 50% inhibition) effect on the production of anti-DNP antibody in this model (Fig. 2) . Subsequently, siomycin was evaluated through in vivo T-cell dependent antibody production model in which female C3H mice were Fig. 2 . Suppressive effect of siomycin on antibody production in DNP-specific antibody production model. immunized with splenocytes from female BALB/c mice as alloantigen. Consequently, it inhibited anti-alloantibody production dose-dependently from 30mg/kg/day down to 0.3mg/kg/day (i.p., day 0-5) (Fig. 3) . These results indicate that siomycin inhibits both T-cell dependent and independent antibody production in vivo, and that it may have potential against some antibody-mediated diseases presently untreatable with available drugs.
Effect of Siomycin in Murine Collagen Arthritis Model
Murine collagen arthritis model in which score of edema is an indicator of the pathology is known as one of rheumatoid arthritis models. We subsequently investigated whether siomycin improves this score.
Siomycin also inhibited total antibody (IgG, IgM and IgA) production dose-dependently from 30mg/kg/day down to 0.3mg/kg/day (i.p., day 0-10) in this model (Fig.   4A ), and led to the observation on day 11 that it significantly improved the score of edema at a dose of 30mg/kg/day (i.p., day 0-10) (Fig. 4B) . The definition of edema is described at methods section.
Discussions
During our screening for B-cell immunosuppressants, we found antibacterial thiazole compound siomyicin from the culture broth of the Actinomycetes strain No.806097. To the best of our knowledge, this is the first time siomycin and its related thiazole antibiotic thiostrepton have been reported to inhibit antibody production. Their inhibitory mechanism against in vitro antibody production was considered to be different from that of T-cell immunosuppressant FK506 because these two thiazole antibiotics suppressed T-cell independent antibody production which FK506 doesn't inhibit to the same degree.
Then, we studied the inhibitory effect of siomycin in two murine antibody production models to investigate whether in vitro profile of siomycin reflect in vivo properties. One model is T-cell independent antibody production using DNP-LPS as antigen, and another model is T-cell dependent using allo-splenocytes as antigen. In the DNP-LPS model it showed moderate suppressive (about 50% inhibition) activity at a dose of 30mg/kg/day (i.p., day 0-3). In the allo-splenocytes model it showed almost complete suppressive property at a dose of 30mg/kg/day (i.p., day 0-5).
Consequently, siomycin showed suppressive effect in both of the antibody production models.
Moreover, in murine collagen arthritis model which is a model for autoimmune disease, siomycin significantly improved the score of edema after administration of 30mg/kg/day. These results suggest that siomycin might exert a therapeutic effectiveness against various autoimmune diseases concerning with autoantibodies through its immunomodulating activity. Moreover, it might bear potential for the treatment of xenograft rejection and chronic allograft rejection.
On the other hand, siomycin and thiostrepton also blocked the alloantigen-induced mixed lymphocyte reaction or anti-CD3 mAb induced T-cell activation suggesting that they might be available for the treatment of acute rejection in allo-transplantation as well.
Cyclic thiazole peptide siomycin and thiostrepton have been known as antibacterial compounds which bind to 50S ribosome resulting in inhibition of synthesis of protein in bacteria12). Interestingly, antibiotic kirromycin, inhibitor of protein synthesis by inactivating EF-Tu13), showed no suppressive activity on B-cells (data not shown).
FRORENZ SASSE et al. reported that cyclic thiazole peptide argyrin B consisting of 8 amino acid residues was a potent inhibitor of T-cell independent antibody production and had slight antibiotic activity14). Combining this report with our data about these antibiotics, there might be some correlation among structural property, antibacterial mechanism and inhibitory effect against T-cell independent antibody production.
We have concluded that antibiotic thiazole compound siomycin is unique immunosuppressant which might have potential for the treatment of some autoimmune diseases, mainly, xenograft rejection, and progression of chronic allograft rejection.
Moreover, there might be a necessity of further investigation of its mechanism as to intracellular responses to identify the related target for the discovery of novel drugs toward antibody-mediated diseases. 
